SEC Form 4 · accession 0001600132-17-000102
Bellerophon Therapeutics, Inc. · BLPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Tasse
Director
Period of report
Sep 22, 2017
Accepted (ET)
Sep 26, 2017 · 4:59 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001600132
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.12 | Sep 22, 2017 | A | 10,000 | A | — | Sep 21, 2027 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1This option was granted on September 22, 2017. This option vests in three equal annual installments over a three-year period from the date of grant.